

# Plant-Derived Cannabinoids Modulate the Activity of Transient Receptor Potential Channels of Ankyrin Type-1 and Melastatin Type-8

Luciano De Petrocellis, Vittorio Vellani, Aniello Schiano-Moriello, Pietro Marini, Pier Cosimo Magherini, Pierangelo Orlando, and Vincenzo Di Marzo

*Endocannabinoid Research Group (L.D., A.S.-M., P.M., P.O., V.D.), Institute of Cybernetics, Consiglio Nazionale delle Ricerche (L.D., A.S.-M.), Pozzuoli (NA), Italy; Institute of Biomolecular Chemistry, Consiglio Nazionale delle Ricerche, Pozzuoli (NA), Italy (P.M., V.D.); Institute of Protein Biochemistry, Consiglio Nazionale delle Ricerche, Napoli, Italy (P.O.); and Department of Biomedical Sciences, University of Modena and Reggio, Modena, Italy (V.V., P.C.M.)*

Received November 29, 2007; accepted March 18, 2008

## ABSTRACT

The plant cannabinoids (phytocannabinoids), cannabidiol (CBD), and  $\Delta^9$ -tetrahydrocannabinol (THC) were previously shown to activate transient receptor potential channels of both vanilloid type 1 (TRPV1) and ankyrin type 1 (TRPA1), respectively. Furthermore, the endocannabinoid anandamide is known to activate TRPV1 and was recently found to antagonize the menthol- and icilin-sensitive transient receptor potential channels of melastatin type 8 (TRPM8). In this study, we investigated the effects of six phytocannabinoids [i.e., CBD, THC, CBD acid, THC acid, cannabichromene (CBC), and cannabigerol (CBG)] on TRPA1- and TRPM8-mediated increase in intracellular  $\text{Ca}^{2+}$  in either HEK-293 cells overexpressing the two channels or rat dorsal root ganglia (DRG) sensory neurons. All of the compounds tested induced TRPA1-mediated  $\text{Ca}^{2+}$  elevation in HEK-293 cells with efficacy comparable with that of mustard oil isothiocyanates (MO), the most potent being CBC

( $\text{EC}_{50} = 60 \text{ nM}$ ) and the least potent being CBG and CBD acid ( $\text{EC}_{50} = 3.4\text{--}12.0 \mu\text{M}$ ). CBC also activated MO-sensitive DRG neurons, although with lower potency ( $\text{EC}_{50} = 34.3 \mu\text{M}$ ). Furthermore, although none of the compounds tested activated TRPM8-mediated  $\text{Ca}^{2+}$  elevation in HEK-293 cells, they all, with the exception of CBC, antagonized this response when it was induced by either menthol or icilin. CBD, CBG, THC, and THC acid were equipotent ( $\text{IC}_{50} = 70\text{--}160 \text{ nM}$ ), whereas CBD acid was the least potent compound ( $\text{IC}_{50} = 0.9\text{--}1.6 \mu\text{M}$ ). CBG inhibited  $\text{Ca}^{2+}$  elevation also in icilin-sensitive DRG neurons with potency ( $\text{IC}_{50} = 4.5 \mu\text{M}$ ) similar to that of anandamide ( $\text{IC}_{50} = 10 \mu\text{M}$ ). Our findings suggest that phytocannabinoids and cannabis extracts exert some of their pharmacological actions also by interacting with TRPA1 and TRPM8 channels, with potential implications for the treatment of pain and cancer.

Transient receptor potential (TRP) ligand-gated cation channels are expressed in many species ranging from yeast to mammals. TRP channels of vanilloid (TRPV), melastatin

(TRPM), and ankyrin (TRPA) types are required for the transduction of sensory stimuli by dorsal root ganglia (DRG) and trigeminal (TG) neurons, some of which mediate noxious thermal or mechanical stimuli, whereas others are polymodal nociceptors. Temperature-sensitive TRP channels are activated by endogenous and exogenous compounds that often excite nociceptors and elicit pain and peripheral inflammation (Levine and Alessandri-Haber, 2007).

TRPV type 1 (TRPV1) is activated by natural products,

This work was supported by grants from GW Pharmaceuticals, UK (to V.D.M.), the Italian Ministry of Education, University and Scientific Research (PRIN 2004057339\_002) (to V.V.), and Fondazione Cassa di Risparmio di Modena and Fondazione Cassa di Risparmio di Carpi (to V.V.).

Article, publication date, and citation information can be found at <http://jpet.aspetjournals.org>.  
doi:10.1124/jpet.107.134809.

**ABBREVIATIONS:** TRP, transient receptor potential; TRPV, TRP channels of vanilloid; TRPA, transient receptor potential channel of ankyrin; DRG, dorsal root ganglia; TG, trigeminal; TRPV1, TRP type 1; CBD, cannabidiol; TRPA1, TRP channel of ankyrin type; TRPM8, TRP channel of melastatin type 8; CGRP, calcitonin gene-related peptide; MO, mustard oil isothiocyanates; THC,  $\Delta^9$ -tetrahydrocannabinol; anandamide, *N*-arachidonoyl-ethanolamine; Capsazepine, *N*-[2-(4-chlorophenyl)ethyl]-1,3,4,5-tetrahydro-7,8-dihydroxy-2*H*-2-benzazepine-2-carbothioamide; PCR, polymerase chain reaction; ANOVA, analysis of variance; *F*, fluorescence;  $F_{\text{max}}$ , maximal fluorescence; CBC, cannabichromene; CBG, cannabigerol; AM251, *N*-(piperidin-1-yl)-5-(4-iodophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1*H*-pyrazole-3-carboxamide; LY320135, 6-methoxy-2-(4-methoxyphenyl)benzo[*b*]-thien-3-yl][4-cyanophenyl]methanone; SR141716A, *N*-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1*H*-pyrazole-3-carboxamide; HU-210, (6*a*,*R*)-*trans*-3-(1,1-dimethylheptyl)-6*a*,7,10,10*a*-tetrahydro-1-hydroxy-6,6-dimethyl-6*H*-dibenzo[*b*,*d*]pyran-9-methanol.

such as capsaicin and resiniferatoxin, noxious heat temperatures ( $\geq 42^{\circ}\text{C}$ ), and low pH ( $< 5.9$ ) (Caterina et al., 1997). A plant cannabinoid (phytocannabinoid), cannabidiol (CBD), also activates and desensitizes TRPV1 (Bisogno et al., 2001; Ligresti et al., 2006), and this effect is responsible for some of the analgesic and anti-inflammatory actions of this compound (Costa et al., 2004, 2007). TRPM8 (Tsavaler et al., 2001) is expressed in both nociceptive and non-nociceptive neurons (Xing et al., 2006). It is gated by low ( $< 25^{\circ}\text{C}$ ) temperatures and chemical cooling compounds such as menthol, eucalyptol, spearmint, WS-3, and icilin (McKemy et al., 2002; Bandell et al., 2004; Chuang et al., 2004), and it is regulated, by being inactivated, in a way opposite to that observed with TRPV1 by protein kinase C-mediated (Premkumar et al., 2005) and protein kinase A-mediated phosphorylation and by the endogenous TRPV1 agonist anandamide (De Petrocellis et al., 2007). TRPA1 (Corey et al., 2004) is found in small-diameter TG and DRG neurons distinct from those expressing TRPM8 but coexpressing TRPV1, substance P, calcitonin gene-related peptide (CGRP), and bradykinin receptors (Story et al., 2003; Bandell et al., 2004; Bautista et al., 2005; Kobayashi et al., 2005). When overexpressed in cells, TRPA1 is activated by lower temperatures compared with TRPM8 (Story et al., 2003), but its role in cold transduction remains controversial (Bautista et al., 2006; Kwan et al., 2006). Previous studies suggested that TRPA1 is activated by elevation of  $[\text{Ca}^{2+}]_i$  during cooling rather than directly by cold (Zurborg et al., 2007). Indeed,  $\text{Ca}^{2+}$ , possibly released from intracellular stores, can directly activate TRPA1 (Jordt et al., 2004; Doerner et al., 2007).

TRPA1 is activated by of mustard oil isothiocyanates (MO) and by other pungent natural products, including allicin, cinnamaldehyde, methylsalicylate, eugenol, and gingerol, as well as by environmental irritants, such as unsaturated aldehydes present in smoke or produced by drug metabolism, all of which elicit a painful burning or pricking sensation (Bandell et al., 2004; Jordt et al., 2004; Bautista et al., 2005; Xu et al., 2006). TRPV1 and TRPM8 instead do not respond to MO. Studies in mice lacking TRPA1 confirmed its role in nociception to irritants (Bautista et al., 2006; Kwan et al., 2006). Intrathecal injection of TRPA1-specific antisense oligonucleotides reverses the hyperalgesia induced by inflammation and nerve injury (Obata et al., 2005). Many TRPA1-activating compounds, like the alkylating agent iodoacetamide, form covalent adducts with thiols and primary amines (Hinman et al., 2006; Macpherson et al., 2007). Topical application of these agents excites sensory nerve fibers, producing acute pain and neurogenic inflammation through peripheral release of substance P, CGRP, purines, and other transmitters. It is noteworthy that MO, like capsaicin with TRPV1, causes functional homologous desensitization of TRPA1 (Ruparel et al., 2008).

MO also induces endothelium-independent and TRPA1-mediated vasorelaxation (Wilson et al., 2002). The plant-derived cannabinoid receptor agonists  $\Delta^9$ -tetrahydrocannabinol (THC) and cannabidiol relax hepatic or mesenteric arteries in vitro by activating CGRP-containing sensory nerve endings that innervate the smooth muscle. This effect is not inhibited by antagonists of cannabinoid receptors, but it is blocked by ruthenium red, is extracellular  $\text{Ca}^{2+}$ -dependent, and persists in TRPV1-deficient mice (Zygmunt et al., 2002). Experiments in TG neurons showed that a subpopu-


lation of capsaicin-sensitive cells is responsive to both MO and THC, suggesting that nociceptors are excited through the same molecular mechanism, involving activation of a  $\text{Ca}^{2+}$ -permeable channel on capsaicin-sensitive sensory neurons. In cells expressing TRPA1, THC or cannabidiol activate this channel (Jordt et al., 2004), thus confirming that TRPA1 might contribute to inflammatory hypersensitivity and vasodilation.

In view of the reported effects of phytocannabinoids on TRP channels (Bisogno et al., 2001; Jordt et al., 2004; Ligresti et al., 2006) and of the proposed therapeutic applications of cannabis extracts (Di Marzo and De Petrocellis, 2006), the aim of present work was to evaluate whether some of these natural products (Fig. 1) influence the activity of heterologously or constitutively expressed TRPA1 and TRPM8 channels on intracellular  $\text{Ca}^{2+}$  in HEK-293 cells and DRG neurons.

## Materials and Methods

**Drugs.** All of the purified phytocannabinoids used were a kind gift from GW Pharmaceutical (Salisbury, Wiltshire, UK). Allyl isothiocyanate from mustard oil, *trans*-cinnamaldehyde, (-)-menthol, and icilin were obtained from Sigma-Aldrich (St. Louis, MO). Ruthenium red was obtained from Alexis Biochemicals Axxora (San Diego, CA), and anandamide and Capsazepine were purchased from Tocris Cookson Ltd. (Bristol, UK). HU-210 was a gift from Prof. R. Mechoulam (Hebrew University of Jerusalem, Israel). All drugs were kept at  $-20^{\circ}\text{C}$ , dry, and under an atmosphere of nitrogen until use. Under these conditions they are stable for at least 12 months. Before use, they were dissolved in dimethyl sulfoxide, whose final concentration in the assay buffer was never higher than 0.2%.

**Stable Transfection of HEK-293 Cells with Rat TRPA1 cDNA and Rat TRPM8 cDNA Containing Plasmids.** HEK-293



**Fig. 1.** Chemical structures of the six plant-derived cannabinoids (phytocannabinoids) tested in this study.

(human embryonic kidney) cells were grown as monolayers in minimum essential medium supplemented with nonessential amino acids, 10% fetal calf serum, and 2 mM glutamine, maintained under 5% CO<sub>2</sub> at 37°C plated on 100-mm diameter Petri dishes, and transfected at approximately 80% confluence with Lipofectamine 2000 (Invitrogen, Carlsbad, CA) by using a plasmid pcDNA3 (Invitrogen) containing the rat TRPA1-cDNA or the rat TRPM8-cDNA (both are kind gift from Profs. Sven-Eric Jordt and David Julius, Department Cellular and Molecular Pharmacology, University of California, San Francisco, CA), according to the manufacturer's protocol. Stably transfected clones were selected by G-418 (Geneticin; 600 µg/ml). Stable transfections were checked by quantitative real-time polymerase chain reaction (PCR).

**Evaluation of TRPM8 and TRPA1 Receptor Transfection Levels by Quantitative Real-Time PCR.** Total RNA was extracted by TRIzol (Invitrogen) according to the manufacturer's recommendations, dissolved in RNA-storage solution (Ambion, Austin, TX), UV-quantified by a BioPhotometer (Eppendorf, New York, NY), and stored at -80°C. RNA aliquots (6 µg) were digested by RNase-free DNase I (Ambion; DNA-free kit) in a 20-µl final volume reaction mixture, to remove contaminating genomic DNA. After DNase digestion, concentration and purity of RNA samples were evaluated by the RNA-6000-Nano microchip assay, using a 2100 Bioanalyzer equipped with 2100 Expert Software (Agilent Technologies, Palo Alto, CA), following the manufacturer's instructions. One microgram of total RNA, as evaluated by the 2100 Bioanalyzer, was reverse transcribed by MoMuLV Superscript III reverse transcriptase (Invitrogen), as described previously. Negative controls (-real-time) were produced by omitting the reverse transcriptase. Quantitative real-time PCR was performed by an iCycler-iQ (Bio-Rad, Hercules, CA) in a 25-µl reaction mixture containing the following: 1× iQ SYBR Green Supermix (Bio-Rad), 10 ng of cDNA (calculated on the basis of the retro-transcribed RNA), and 330 nM for each primer. The amplification profile consisted of an initial denaturation of 2 min at 94°C and 40 cycles of 30 s at 94°C, annealing for 30 s at TaOpt (optimum annealing temperature, see below), and elongation for 45 s at 68°C. Fluorescence data were collected during the elongation step. A final extension of 7 min was carried out at 72°C, followed by melt-curve data analysis. Optimized primers for SYBR Green analysis (and relative TaOpt) were designed by the Beacon-Designer software 6.0 version (Biosoft International, Palo Alto, CA) and were synthesized (HPLC-purification grade) by MWG-Biotech AG (Ebersberg, Germany). Assays were performed in quadruplicate (maximal ΔCt of replicate samples, <0.5), and a standard curve from consecutive 5-fold dilutions (100–0.16 ng) of the cDNAs was included, for PCR-efficiency determination. Relative expression analysis, correct for PCR efficiency and normalized with respect to reference genes β-actin and glyceraldehyde 3-phosphate dehydrogenase, was performed by GENEX software (Bio-Rad) for group-wise comparison and statistical analysis.

**Experiments in HEK-293 Cells Overexpressing the Rat TRPA1 or TRPM8 Channels.** Cells were plated on 100-mm diameter Petri dishes and after 3 days were loaded for 1 h at room temperature with the cytoplasmic calcium indicator Fluo4-AM (4 µM; Invitrogen) containing Pluronic (0.02%; Invitrogen). Cells were washed twice in Tyrode's buffer (145 mM NaCl, 2.5 mM KCl, 1.5 mM CaCl<sub>2</sub>, 1.2 mM MgCl<sub>2</sub>, 10 mM D-glucose, and 10 mM HEPES, pH 7.4), resuspended in Tyrode's buffer, and transferred to the quartz cuvette of the spectrofluorimeter (λ<sub>ex</sub> = 488 nm; λ<sub>em</sub> = 516 nm) (Perkin-Elmer LS50B; PerkinElmer Life and Analytical Sciences, Waltham, MA) under continuous stirring. [Ca<sup>2+</sup>]<sub>i</sub> was determined before and after the addition of various concentrations of test compounds. EC<sub>50</sub> values were determined as the concentration of test substances required to produce half-maximal increases in [Ca<sup>2+</sup>]<sub>i</sub>. Curve fitting and parameter estimation were performed with GraphPad Prism (GraphPad Software Inc., San Diego, CA). Phytocannabinoids were added 5 min before stimulation of cells with icilin or menthol. IC<sub>50</sub> values were determined again using Graph-

Pad Prism, because the concentration exerting a half-maximal inhibition of agonist induced increases of [Ca<sup>2+</sup>]<sub>i</sub>.

The efficacy of the agonists was first determined by normalizing their effect to the maximal effect on [Ca<sup>2+</sup>]<sub>i</sub> observed with 4 µM ionomycin. Subsequently, the effects of TRPA1 agonists are expressed as a percentage of the effect obtained with 100 µM MO. In experiments in TRPM8-HEK-293 cells, varying doses of phytocannabinoids were added 5 min (or in some experiments 15 min) before EC<sub>90</sub> concentrations of menthol (50 µM) or icilin (0.25 µM). Data were expressed as the concentration exerting a half-maximal inhibition of agonist effect (IC<sub>50</sub>), which was calculated using GraphPad software. The effect on [Ca<sup>2+</sup>]<sub>i</sub> exerted by the agonist alone was taken as 100%.

**Statistics.** Statistical analysis of the data was performed by analysis of variance (ANOVA) at each point followed by the Bonferroni test. Differences were considered significant at *P* < 0.05.

**Animals and Cells.** DRG were prepared as described previously. DRG neurones from neonatal Sprague-Dawley rats (P7-P14) or adult mice were cultured as described previously (Vellani et al., 2001, 2004). In brief, isolated ganglia were digested in collagenase (type IV; Worthington Biochemical, Lakewood, NJ), mechanically dissociated, plated on glass coverslips coated with poly-L-lysine and laminin (Sigma-Aldrich), and maintained in Dulbecco's modified Eagle's medium (Invitrogen) containing 100 ng/ml nerve growth factor (100 ng/ml<sup>-1</sup>; Promega, Madison, WI), 10% fetal bovine serum, penicillin, and streptomycin. All animal procedures were carried out in accordance with Italian legislation. Neonatal rats (P7-P14) were killed by decapitation under halothane anesthesia, DRG were isolated, and neurons were dissociated and cultured. For dose-response experiments, approximately 10,000 to 30,000 neurons were used for each data point. Cells were exposed to capsaicin, mustard oil, and ionomycin; all of these treatments, which produce massive calcium influx from extracellular space, caused an increase in calcium in the cytoplasm.

**Calcium Imaging in DRG Cultures.** Calcium measurements were performed after 1 to 3 days in culture, DRG neurons were loaded in a serum-free medium for 10 min with the calcium-sensitive fluorescent indicator Fluo-4 AM (10 µM; Invitrogen). Experiments were carried out in the following extracellular solution: 145 mM NaCl, 4 mM KCl, 1.8 mM CaCl<sub>2</sub>, 1 mM MgCl<sub>2</sub>, 10 mM HEPES, and 4 mM glucose, neutralized to pH 7.4 with NaOH. Coverslips were mounted onto an upright E600 microscope (Nikon, Florence, IT) equipped with an Andor Technology imaging system (Belfast, Northern Ireland, UK). Fluo-4 AM was excited with 488-nm light, which was generated by a monochromator (Cairn Research, Faversham, UK), and images of the fluorescence (*F*) were captured every 2 s using a time course software package (Andor iQ; Andor Technology). The fluorescent images were acquired by an electron multiplying CCD camera (Andor Technology), and the fluorescence intensity in specific regions of interest was measured. Neurons were distinguished from non-neuronal cells at the start or at the end of the experiment by applying 25 mM KCl, which induce a rapid increase of [Ca<sup>2+</sup>]<sub>i</sub> in neurons. To identify neurons responding to both phytocannabinoids and allyl isothiocyanate or icilin, phytocannabinoids were added to DRG cultures at 100 µM concentration, 10 min before 100 µM MO or 1 µM icilin, and [Ca<sup>2+</sup>]<sub>i</sub> fluorescence was recorded for 180 s after the addition of each agonist. At the end of the experiment, the maximal fluorescence (*F*<sub>max</sub>) was obtained by application of the calcium ionophore ionomycin (10 µM; Calbiochem, La Jolla, CA) in the presence of high Ca<sup>2+</sup> (30 mM) and K<sup>+</sup> (125 mM). Calcium imaging data are expressed as *F*/*F*<sub>max</sub>. All experiments were performed at room temperature (23–25°C). In general, DRG neurons from neonatal rats were preferred for ease of supply and culture preparation. The main findings in DRG neurons isolated from neonatal rats were reproduced in cells from adult mice (data not shown), suggesting that the effects seen were neither species- nor age-dependent.

**Morphology of DRG Neurons.** DRG neuronal size was measured from calibrated images recorded in transmitted light before

calcium imaging experiments. The area of individual neurons responding to specific agonists was measured by calculating the area of a corresponding region of interest drawn with Andor iQ software. Distribution histograms were generated using SigmaPlot 8.0 computer software (Systat Software Inc., San Jose, CA).


**Statistics.** The data are presented as mean  $\pm$  S.E.M. values. Statistical analyses were performed using one-way ANOVA. Follow-up analysis was performed using the Bonferroni test. Total cell count and distribution of cell size were compared using the ANOVA comparison of log-transformed distribution data.

## Results

**HEK-293 Cell Transfection.** We have stably transfected HEK-293 cells with the plasmid pcDNA3 containing the rat recombinant TRPA1 cDNA, thus generating cells (denoted with "TRPA1-HEK-293") that, as assessed by real-time PCR, express high levels of TRPA1 transcript. This transcript was absent in HEK-293 cells stably transfected with cDNA encoding rat TRPM8 (denoted with "TRPM8-HEK-293"), which instead express high levels of TRPM8 transcript (De Petrocellis et al., 2007), and in HEK-293 cells that had not been transfected with the pcDNA3 plasmid and were treated with only Lipofectamine (data not shown).

**TRPA1 Is Activated by Cinnamaldehyde and Other Sensory Compounds.** Using a fluorometric test, we showed that rat TRPA1-HEK293 cells exhibit a sharp increase in intracellular  $[Ca^{2+}]_i$  upon application of MO or cinnamaldehyde, two compounds known to activate TRPA1. Using this test, we determined the concentration for half-maximal activation to be  $13.0 \pm 4.1 \mu\text{M}$  for cinnamaldehyde and  $2.5 \pm 0.7 \mu\text{M}$  for MO (Fig. 2A). Ruthenium red, a known blocker of TRPA1, inhibited the effect (data not shown). Cinnamaldehyde and MO did not activate TRPV1-HEK-293 or TRPM8-HEK-293 cells (data not shown). Analogous to what was reported by Jordt et al. (2004), THC also increased  $[Ca^{2+}]_i$  with an  $EC_{50}$  of  $0.23 \pm 0.03 \mu\text{M}$  (Fig. 2A).


**TRPA1 Is Activated by Phytocannabinoids.** All of the phytocannabinoids that were tested increased  $[Ca^{2+}]_i$  in TRPA1-HEK-293 cells. The  $EC_{50}$  values were (Hill slopes are between parentheses) as follows: cannabichromene (CBC),  $0.06 \pm 0.02 \mu\text{M}$  ( $1.1 \pm 0.3$ ); CBD,  $0.096 \pm 0.012 \mu\text{M}$  ( $0.8 \pm 0.1$ ); THC acid,  $0.24 \pm 0.03 \mu\text{M}$  ( $1.9 \pm 0.5$ ); CBD acid,  $12.0 \pm 8.8 \mu\text{M}$  ( $0.5 \pm 0.1$ ); cannabigerol (CBG),  $3.4 \pm 1.0 \mu\text{M}$  ( $0.6 \pm 0.1$ ) (means  $\pm$  S.E.,  $n = 4$ ; Fig. 3B). In some cases, the response at  $100 \mu\text{M}$  resulted higher than that of MO (THC =  $117 \pm 12\%$ ; CBC =  $117 \pm 10\%$ ; and CBG =  $126 \pm 11\%$ ), whereas the acids (CBD acid =  $74 \pm 6\%$  and THC acid =  $78 \pm 8\%$  of MO) showed a weaker effect. Therefore, CBD acid and THC acid behaved as partial agonists in this assay compared with MO, and this might be used for the future development of TRPA1 antagonists. Among the phytocannabinoids, only CBD increased  $[Ca^{2+}]_i$  also when tested in nontransfected HEK-293 cells, with a half-maximal activation value of  $0.7 \pm 0.2 \mu\text{M}$  but with a very low efficacy of  $26 \pm 3\%$  at  $50 \mu\text{M}$ . Therefore, the curves used to calculate its potency and efficacy at TRPA1 were subtracted from the corresponding values obtained in nontransfected cells. The synthetic cannabinoid receptor agonist, HU-210, did not exert any effect on TRPA1-HEK-293 cells up to a  $10 \mu\text{M}$  concentration (data not shown). Note that 5-min preincubation of TRPA1-HEK-293 cells with CBC or CBG prevented the elevation of  $[Ca^{2+}]_i$  induced by MO in TRPA1-HEK-293 cells,



**Fig. 2.** A, dose-related effects of THC, MO, and cinnamaldehyde, or various phytocannabinoids (CBD, CBC, CBG, THC acid, and CBD acid) (B) on  $[Ca^{2+}]_i$  in HEK-293 cells stably transfected with the rat recombinant TRPA1 channel. No response was observed in nontransfected cells, with the exception of CBD (see *Results*). C, dose-related effect of 5-min preincubation of TRPA1-HEK-293 cells with CBC or CBG on MO ( $100 \mu\text{M}$ )-induced elevation of  $[Ca^{2+}]_i$ . Data are expressed as percentage of the maximal effect observed with MO. The effect observed for each dose of CBD in nontransfected cells was subtracted from that observed in stably transfected cells. Data are the means  $\pm$  S.E. of  $n = 4$  separate determinations. S.E. bars are not shown for the sake of clarity and were never higher than 5% of the means. In C, the effect of concentrations  $\geq 10^{-7}$  M for CBC, and of concentrations  $\geq 10^{-6}$  M for CBG, was statistically significant ( $P < 0.01$ , as assessed by ANOVA followed by the Bonferroni test).

with  $IC_{50}$  values of  $0.09 \pm 0.02$  and  $1.0 \pm 0.01 \mu\text{M}$ , respectively (Fig. 2C).

**Phytocannabinoids Mobilize Intracellular Calcium in MO-Responding DRG Neurons.** Some phytocannabinoids were also tested in DRG neurons using a calcium imaging approach, and, at a  $100 \mu\text{M}$  concentration, they elicited robust increases in intracellular  $Ca^{2+}$  in a subpopulation of DRG neurons that also responded to MO. Neurons responding to CBC were predominantly of small and medium diameter. In adult mice, the CBC-responding population had an average area of  $391 \pm 9 \mu\text{m}^2$ , and the whole neuronal population had an average area of  $336 \pm 7 \mu\text{m}^2$  (12 coverslips in four cultures); this difference was statistically significant




**Fig. 3.** Effect of CBC on  $[\text{Ca}^{2+}]_i$  in neonatal DRG neurons as assessed by calcium imaging. A, size distribution of MO (100  $\mu\text{M}$ )-responding (light gray) and CBC (100  $\mu\text{M}$ )-responding (dark gray) DRG neurons over the total population (very light gray). B, average kinetics of the response of DRG neurons to CBC (100  $\mu\text{M}$ )—in several cases, the onset of the rise of  $[\text{Ca}^{2+}]_i$  was slower or more rapid. C, dose-related effect of CBC. Data are the means  $\pm$  S.E. of  $n = 10,000$  to 30,000 neurons.

at  $P < 0.0001$ . The neurons from neonatal rats responding to CBC were predominantly of small and medium diameter (Fig. 3A), but the presence of some very large neurons increased the mean area of CBC-responsive neurons to  $429 \pm 20 \mu\text{m}^2$ , compared with an average of  $407 \pm 9 \mu\text{m}^2$  for the whole neuronal population (no statistically significant difference). The  $\text{Ca}^{2+}$  response to CBC (or MO) was often elicited with a substantial delay: in neurons from neonatal rats, the

$\text{Ca}^{2+}$  rise started with a latency of  $35 \pm 4$  s (range, 2–152 s) after exposure to CBC, but once the  $\text{Ca}^{2+}$  increase had started, it grew steeply, reaching a peak within  $79 \pm 3$  s from CBC application (range, 22–212 s) (Fig. 3B). This complex kinetics might be related to poor permeability through the plasma membrane or complex actions at the intracellular level, and it has also been observed in a recent study with synthetic cannabinoids (Akopian et al., 2008). The average peak amplitude for 100  $\mu\text{M}$  CBC was  $0.79 \pm 0.02 \Delta F/F_{\text{max}}$  (range, 0.05–0.96  $\Delta F/F_{\text{max}}$ ). Recovery from peak was rather slow and incomplete, because the  $\text{Ca}^{2+}$  response often remained elevated for several minutes even after removal of CBC. In neonatal DRGs, CBC exhibited an  $\text{EC}_{50} = 34.3 \mu\text{M}$  (Fig. 3C), whereas CBD and CBG were only tested at 100  $\mu\text{M}$  and were less efficacious, although they acted on a higher number and larger population of neurons (see below, and data not shown). The maximal concentration of CBC tested in DRG neurons (200  $\mu\text{M}$ ) was probably nonsaturating, but we did not test higher concentrations due to poor solubility of these lipid compounds and to avoid the risk of nonspecific effects. The lack of available specific antagonists for TRPA1 prevented us from a further pharmacological characterization of the CBC effect in DRG neurons. However, some responses to CBC were seen in neuronal cells that, when further tested with MO, did not respond, probably due to desensitization of TRPA1. Indeed, previous exposure of DRG neurons to low doses of phytocannabinoids, which were unable to produce  $\text{Ca}^{2+}$  signals, prevented calcium signals at higher doses. This behavior was observed with CBD, CBC, and CBG (data not shown) and is similar to the one occurring in TRPA1-HEK-293 cells (see Fig. 2C).

**Effect of Phytocannabinoids on TRPM8 Activation by Icilin.** As shown previously (De Petrocellis et al., 2007), icilin dose-dependently elevated intracellular  $\text{Ca}^{2+}$  in TRPM8-HEK-293 cells, but not in nontransfected cells, with an  $\text{EC}_{50}$  of  $0.19 \pm 0.03 \mu\text{M}$ . Preincubation (5 min) with different doses of phytocannabinoids, and then continued incubation with icilin (0.25  $\mu\text{M}$ ) of TRPM8-HEK-293 cells, caused an inhibition of TRPM8 response to icilin (Fig. 4A). The  $\text{IC}_{50}$  values (against icilin at 0.25  $\mu\text{M}$ ) were as follows (Hill slopes are between parentheses): THC,  $0.16 \pm 0.01 \mu\text{M}$  ( $1.8 \pm 0.1$ ); THC acid,  $0.14 \pm 0.02 \mu\text{M}$  ( $1.9 \pm 0.1$ ); CBD,  $0.08 \pm 0.01 \mu\text{M}$  ( $0.8 \pm 0.1$ ); CBD acid,  $0.9 \pm 0.1 \mu\text{M}$  ( $1.4 \pm 0.1$ ); and CBG,  $0.14 \pm 0.01 \mu\text{M}$  ( $1.0 \pm 0.04$ ) (means  $\pm$  S.E.,  $n = 4$ ). CBC did not inhibit the effect of icilin in these cells. The effects of concentrations  $\geq 10^{-7}$  M of all compounds, with the exception of CBC, and of concentrations  $\geq 10^{-6}$  M for CBD acid were statistically significant ( $P < 0.01$ ). A longer (15 min) preincubation time did not dramatically modify these values (between 8 and 15% increase; data not shown), whereas shorter preincubation times were not tested.

**Effect of Phytocannabinoids on TRPM8 Activation by Menthol.** In agreement with previous studies (De Petrocellis et al., 2007), menthol dose-dependently elevated intracellular  $\text{Ca}^{2+}$  in TRPM8-HEK-293 cells, in a way mediated by TRPM8 because no effect was detected in the wild-type HEK-293 cells under similar conditions (data not shown). The  $\text{EC}_{50}$  for menthol was  $40.9 \pm 15.1 \mu\text{M}$ . Pretreatment (5 min), and then continued incubation, of TRPM8-HEK-293 cells with phytocannabinoids reduced the effect of menthol on  $[\text{Ca}^{2+}]_i$  in a dose-dependent manner (Fig. 4B). The  $\text{IC}_{50}$  values (against menthol at 50  $\mu\text{M}$ ) were as follows (Hill




**Fig. 4.** Dose-related inhibition by various phytocannabinoids (THC, CBD, CBG, THC acid, and CBD acid) on icilin (A) and menthol (B)-induced elevation of  $[Ca^{2+}]_i$  in HEK-293 cells stably transfected with the rat recombinant TRPM8 channel. Icilin and menthol elicited no response in nontransfected cells (see *Results*). Data are expressed as percentage of the maximal effect observed with either icilin (0.25  $\mu M$ ) (A) or menthol (50  $\mu M$ ) (B). The effect observed for each dose of CBD was corrected for its stimulatory effect on  $[Ca^{2+}]_i$  observed in nontransfected cells. Data are the means  $\pm$  S.E. of  $n = 4$  separate determinations. S.E. bars are not shown for the sake of clarity and were never higher than 5% of the means. In both A and B, the effect of concentrations  $\geq 10^{-7}$  M of all compounds, with the exception of CBC, and of concentrations  $\geq 10^{-6}$  M for CBD acid was statistically significant ( $P < 0.01$ , as assessed by ANOVA followed by the Bonferroni test).

slopes are between parentheses): THC,  $0.15 \pm 0.02 \mu M$  ( $1.4 \pm 0.1$ ); THC acid,  $0.07 \pm 0.01 \mu M$  ( $1.0 \pm 0.1$ ); CBD,  $0.14 \pm 0.01 \mu M$  ( $1.7 \pm 0.4$ ); CBD acid,  $1.6 \pm 0.4 \mu M$  ( $0.7 \pm 0.2$ ); and CBG,  $0.16 \pm 0.03 \mu M$  ( $0.9 \pm 0.2$ ). CBC did not inhibit the effect of menthol in these cells. The effects of concentrations  $\geq 10^{-7}$  M of all compounds, with the exception of CBC, and of concentrations  $\geq 10^{-6}$  M for CBD acid were statistically significant ( $P < 0.01$ ).

**Effect of Phytocannabinoids on Icilin-Responding DRG Neurons.** Because THC acid and THC are quite efficacious at TRPA1 (present data) and CBD also activates TRPV1, we used CBG, which was the least potent compound on TRPA1 and one of the most potent ones at antagonizing TRPM8-induced elevation of  $[Ca^{2+}]_i$  in TRPM8-HEK-293 cells (present data), to study the effect on DRG neurons. Although CBG (100  $\mu M$ ) also elevated  $[Ca^{2+}]_i$  in neurons that did not respond to icilin (Fig. 5A), possibly due to interaction with other TRP channels (notably CBG, apart from TRPA1, also activates TRPV1 at high concentrations), it did inhibit the response to icilin in icilin-responding DRG neurons in a dose-dependent way ( $IC_{50} = 4.5 \mu M$ , 5-min preincubation; Fig. 5B). Note that, anandamide, which was previously found to inhibit menthol- and icilin-induced response in TRPM8-HEK-293 cells (De Petrocellis et al., 2007), also inhibited the icilin response in DRG neurons with a potency similar to that of CBG (Fig. 5C). The inhibitory effect of CBG was unlikely due to its elevation of  $[Ca^{2+}]_i$ , and subsequent TRPM8 desensitization, for three reasons: 1) the size distribution of icilin-responding neurons was different from the size distribution of CBG-responding cells, the former being composed exclusively of small, and the latter of medium to large, neurons, with very little overlap (Fig. 5A); 2) almost no individual neuron responding to icilin responded to CBG (100  $\mu M$ ) with further elevation of  $[Ca^{2+}]_i$ , again suggesting that

tribution of icilin-responding neurons was different from the size distribution of CBG-responding cells, the former being composed exclusively of small, and the latter of medium to large, neurons, with very little overlap (Fig. 5A); 2) almost no individual neuron responding to icilin responded to CBG (100  $\mu M$ ) with further elevation of  $[Ca^{2+}]_i$ , again suggesting that



**Fig. 5.** Effect of CBG on basal and icilin (1  $\mu M$ )-induced elevation of  $[Ca^{2+}]_i$  in neonatal DRG neurons as assessed by calcium imaging. A, size distribution of the entire DRG neuron population of neurons responding to either icilin (1  $\mu M$ ) (black bars) or CBG (100  $\mu M$ ) (white bars) with increased  $[Ca^{2+}]_i$ . B, dose-related effect of CBG on icilin-induced elevation of  $[Ca^{2+}]_i$ . C, dose-related effect of anandamide on icilin-induced elevation of  $[Ca^{2+}]_i$ . Data are the means  $\pm$  S.E. of  $n = 10,000$  to 30,000 neurons.

CBG-induced calcium response occurred only in non-TRPM8-expressing neurons; and 3) when it inhibited the icilin response, CBG was inactive at elevating  $[Ca^{2+}]_i$ .

**Effects of CB<sub>1</sub> Receptor Antagonists on Phytocannabinoid-Induced Responses.** Because (especially in DRG neurons) some of the effects of the phytocannabinoids were observed at concentrations higher than 10  $\mu$ M, the possibility exists that these effects are mediated by interaction with CB<sub>1</sub> receptors, which are expressed in these sensory neurons as well as, to some extent, in HEK-293 cells (De Petrocellis et al., 2007). Instead, CB<sub>2</sub> receptors are not present in HEK-293 cells and DRG neurons. For this reason, we tested the effect of CB<sub>1</sub> receptor antagonists on the effects of CBC on TRPA1 and CBG on TRPM8. In TRPA1-HEK-293 cells, AM251 and LY320135 reduced the MO (100  $\mu$ M)-induced effect on  $[Ca^{2+}]_i$  at concentrations  $\geq 1$   $\mu$ M and, therefore, were tested on CBC at a concentration of 0.5  $\mu$ M, which are well above their  $K_i$  for CB<sub>1</sub> receptors (Gatley et al., 1997; Felder et al., 1998). AM251 nonsignificantly reduced ( $P > 0.05$ ) the effect of CBC (10  $\mu$ M) by  $24 \pm 9\%$  (mean  $\pm$  S.D.,  $n = 3$ ), whereas LY320135 exerted no effect ( $4 \pm 1\%$  inhibition, mean  $\pm$  S.D.,  $n = 3$ ). In TRPM8-HEK-293 cells, AM251, as previously shown for SR141716A (De Petrocellis et al., 2007), potently inhibited icilin (0.25  $\mu$ M)-induced elevation of  $[Ca^{2+}]_i$  at concentrations (0.1–0.2  $\mu$ M and above) similar to those required to antagonize CB<sub>1</sub>, whereas LY320135 was inactive at concentrations  $< 0.5$   $\mu$ M. Therefore, we only tested this compound on CBG (10  $\mu$ M) inhibition of icilin-induced elevation of  $[Ca^{2+}]_i$ . LY320135 (0.1 and 0.25  $\mu$ M) exerted no statistically significant inhibition of CBG effect ( $+6 \pm 2$  and  $-15 \pm 8\%$ ,  $P > 0.05$ , means  $\pm$  S.D.,  $n = 3$ ).

In cultured DRG cells, LY320135 at concentrations up to 10  $\mu$ M per se did not produce any effect on intracellular calcium concentration. A total of 100  $\mu$ M CBC produced a  $Ca^{2+}$  rise in  $29.6 \pm 3.5\%$  of cultured DRG neurons and in  $25.6 \pm 2.6\%$  when 1  $\mu$ M LY320135 was added 2 to 4 min before CBC addition; this difference was not statistically significant (data were from three separate cultures). Likewise, when 10  $\mu$ M LY320135 was present, the effect of 100  $\mu$ M CBC was seen in  $22.5 \pm 1.5\%$  of cultured DRG neurons, and, again, the difference was not statistically significant. We then applied solutions containing a mixture of CBG, LY320135, and icilin to assess whether the inhibitory effect of CBG on icilin-induced  $Ca^{2+}$  elevation was due to CB<sub>1</sub> receptors. However, the combination of such compounds, even if icilin was applied after preapplication of a mixture of CBG (100  $\mu$ M) and LY320135 (1 or 10  $\mu$ M), produced large calcium responses in a significant number of DRG non-neuronal cells present in the culture and in many large-sized DRG neurones, which normally do not respond to icilin (see Fig. 5). Due to this aberrant effect of LY320135/CBG/icilin, the role of CB<sub>1</sub> receptors in CBG modulation of icilin response could not be fully investigated in DRG neurons.

## Discussion

In this study, we have described for the first time the capability of several phytocannabinoids to influence the TRPA1- and TRPM8-mediated elevation of  $[Ca^{2+}]_i$  in HEK-293 cells overexpressing these channels and in DRG sensory neurons. Because elevation of  $[Ca^{2+}]_i$  plays a fundamental role in the function of these channels, which is not limited to

induce excitation and depolarization of sensory neurons and subsequent thermoreception, but might also play a role in the survival of some cancer cells (Zhang and Barritt 2004), as well as in the mobilization of intracellular calcium and subsequent activation of  $Ca^{2+}$ -operated channels (Thebault et al., 2005; Mahieu et al., 2007) and the sensitization/desensitization of other channels including many TRPs (Levine and Alessandri-Haber, 2007), these data raise the possibility that the studied phytocannabinoids might exert some of their several pharmacological activities by also regulating TRPA1 and TRPM8 activity. Phytocannabinoids, and CBC in particular, potently and efficaciously elevated  $[Ca^{2+}]_i$  in TRPA1-expressing, but not wild-type, HEK-293 cells and in MO-responding DRG neurons. The potency of CBC in DRG neurons ( $\sim 34$   $\mu$ M) was, as expected when using cells that constitutively express receptors, considerably lower than that in HEK-293 cells (61 nM), although the efficacy was comparable with that of MO in both cell types. It is interesting to note that the rank of potency in TRPA1-HEK-293 cells (CBC > CBD > THC > THC-acid > CBG > CBD-acid) reflects the expected electrophilic nature of the hydroxy group in position 1. This is highest in CBC, in which a partly unsaturated, electron-attracting pyrane group is conjugated with the aromatic cycle, and lowest in THC acid, CBD acid, and CBG, in which the pyrane moiety is absent and the strong electron donor groups are present. However, the only exception to this rule is CBD, which might exert a more potent effect due to its ability to elevate  $[Ca^{2+}]_i$  also in a TRPA1-independent manner and to the well known property of  $Ca^{2+}$  to directly activate TRPA1. Therefore, given the well established fact that TRPA1 are activated by compounds containing electrophilic groups, which seem to form covalent bonds with cysteine groups of the protein, thereby gating the passage of calcium (Hinman et al., 2006; Macpherson et al., 2007), these observations suggest that phytocannabinoids might also activate the channel in this way. However, specific studies, including a direct demonstration of the interaction between, e.g., CBC and TRPA1 obtained by means of electrophysiological (i.e., patch-clamp) measurements and site-directed mutagenesis of the cDNA encoding this protein, need to be carried out to demonstrate that this hypothesis is correct.

Although in DRG neurons a large superimposition between the size of cells responding to MO and that of the cells responding to CBC was observed, the kinetics of  $[Ca^{2+}]_i$  elevation induced by the phytocannabinoid was different from that observed in TRPA1-HEK-293 cells. This phenomenon, like the lower potency observed in these neurons, might be due to the lower degree of expression of TRPA1 in sensory neurons compared with HEK-293 cells stably transfected with TRPA1 cDNA, as well as to the presence of other channels that might respond to CBC. These channels are unlikely to be TRPV1 channels (which are highly coexpressed in TRPA1-expressing neurons), because we have previously found that both human and rat recombinant TRPV1 is insensitive to CBC (Ligresti et al., 2006). However, other channels, including but not limited to TRPV channels, might also be activated by this compound and influence the kinetics of the calcium response in sensory neurons. It is unfortunate that, to date, the lack of specific TRPA1 antagonists did not allow us to rule out the possibility that other molecular targets might contribute to the CBC effect on  $[Ca^{2+}]_i$  in these

neurons. At any rate, in view of the vasodilatory and nociceptive responses caused by TRPA1 activation (Bautista et al., 2005), and in view of their easy desensitization by TRPA1 agonists (Ruparel et al., 2008), our findings suggest that the anti-inflammatory and antinociceptive effects of cannabis extracts and CBD might be due, in part, to the capability of phytocannabinoids to activate/desensitize TRPA1. In this study, we have found that preincubation with CBC and CBG prevents the elevation of  $[Ca^{2+}]_i$  in TRPA1-HEK-293 cells and DRG neurons. Accordingly, during the revision process of the present article, a study reported that, in trigeminal sensory neurons, some synthetic cannabinoids, by activating TRPA1 at concentrations similar to those reported here for phytocannabinoids in DRG neurons, desensitize MO-induced and TRPA1-mediated currents (Akopian et al., 2008).

We have also shown here that although TRPM8 is not activated by phytocannabinoids, its effect on  $[Ca^{2+}]_i$  elevation, induced by two different agents (menthol and icilin), is inhibited by some of these compounds. This finding was not particularly unexpected because we have previously shown that the endocannabinoids, anandamide and *N*-arachidonyldopamine, antagonize the TRPM8-mediated response to menthol and icilin (De Petrocellis et al., 2007), and several authors have reported that agents that activate TRPV1 (and CBD and CBG are listed among these) usually produce the opposite effect on TRPM8 channels (see Introduction). Here, we found that all of the phytocannabinoids tested, including THC, and with the exception of CBD acid (which was a relatively weak antagonist) and CBC (which was completely inactive), were nearly equipotent at antagonizing the TRPM8-mediated response to icilin and menthol. TRPM8 antagonism by CBG was also found to occur in DRG neurons, and, in this case, although this compound exerted a stimulatory effect on some non-icilin-responding neurons of medium-to-large diameter per se, in those small neurons that did respond to icilin, the potency of the inhibitory effect on  $[Ca^{2+}]_i$  elevation ( $IC_{50} \sim 4.5 \mu M$ ) was not exceedingly lower than that observed in TRPM8-HEK-293 cells ( $IC_{50} \sim 0.14 \mu M$ ). Although the role of TRPM8 in nociception (other than that induced by cooling) is still controversial, this channel has been strongly associated with cancer cell proliferation, particularly in prostate carcinoma (Tsavaler et al., 2001; Thebault et al., 2005). In fact, it has been shown that the survival of prostate cancer cells depends on the presence of TRPM8 channels, and hence TRPM8 antagonists have been suggested as a potential therapy for the treatment of this type of cancer (Zhang and Barritt 2004; Bidaux et al., 2007). Specific studies in this direction need to be performed before it can be suggested that phytocannabinoids with antagonist activity at TRPM8 can be used as anticancer agents. Furthermore, the nature of the interaction between phytocannabinoids and TRPM8 needs to be investigated in detail, for example, through the use of electrophysiological (i.e., patch-clamp) measurements. In fact, it is possible that these compounds influence the capability of icilin and menthol to gate TRPM8 channels not just because they are interacting with their binding sites on the protein, but also because they cause effects downstream of TRPM8 gating.

In DRG neurons, where, as stated above, the effects described here were observed at concentrations of phytocannabinoids generally higher than  $1 \mu M$ , it is possible that these lipophilic compounds also act either by membrane bi-

layer perturbation or by activating cannabinoid  $CB_1$  receptors, which are known to be expressed in sensory neurons and, to some extent, also in HEK-293 cells (De Petrocellis et al., 2007). However, although it has been suggested that lipophilicity is a "component, but not a primary determinant of pharmacological activity in the cannabinoids" (Thomas et al., 1990), we found that in both DRG neurons and HEK-293 cells,  $CB_1$  receptor antagonists do not significantly affect the ability of CBC to activate TRPA1-mediated elevation of intracellular  $Ca^{2+}$ , and that at least in HEK-293 cells also, the inhibitory effect of CBG on icilin-induced responses was not influenced by one of these antagonists. Accordingly, Akopian et al. (2008) showed that two very potent  $CB_1$  and/or  $CB_2$  agonists activate TRPA1 in trigeminal neurons in a way completely independent from cannabinoid receptors.

In conclusion, we have reported here for the first time the potent and efficacious modulatory effects by some phytocannabinoids on TRPA1- and TRPM8-mediated  $[Ca^{2+}]_i$  elevation, and in particular the stimulation of CBC on TRPA1 activity, and the inhibition by THC, THC acid, CBD, and CBG of TRPM8 activity in HEK-293 cells stably transfected with the cDNAs encoding for the two proteins. Similar effects were also found to occur in DRG sensory neurons. The exact molecular nature of these interactions, as well as their potential therapeutic relevance, will have to be addressed in future studies. Nevertheless, in view of the following observations: 1) TRPA1 and TRPM8 participate in pain transduction (Obata et al., 2005); 2) TRPA1 stimulation by synthetic cannabinoids causes its desensitization and is responsible for some of the analgesic effects of these compounds (Akopian et al., 2008; Ruparel et al., 2008); 3) the phytocannabinoids tested here can represent up to 0.06 (CBC), 0.62 (CBG), 0.86 (CBD), 9.7 (CBD acid), 13.0 (THC acid), and 1.34 (THC) percent in weight of dried cannabis flowers (personal communication from Dr. P. Gibson and A. Sutton, GW Pharmaceuticals); and 4) the rat TRPA1 and TRPM8 (used in the present study) compared to their human orthologs (GenBank protein sequences: TRPA1 *Rattus norvegicus* NP\_997491; TRPA1 *Homo sapiens* NP\_015628; TRPM8 *R. norvegicus* NP\_599198; and TRPM8 *H. sapiens* NP\_076985) exhibit extremely similar amino acid sequences (89% for TRPA1 and 97% for TRPM8) and analogous predicted three-dimensional structure; our findings suggest that some of the analgesic effects of cannabis extracts reported in clinical trials (for review, see Di Marzo and De Petrocellis, 2006) might be due to interaction with TRPA1 and TRPM8 channels.

## References

- Akopian AN, Ruparel NB, Patwardhan A, and Hargreaves KM (2008) Cannabinoids desensitize capsaicin and mustard oil responses in sensory neurons via TRPA1 activation. *J Neurosci* **28**:1064–1075.
- Bandell M, Story GM, Hwang SW, Viswanath V, Eid SR, Petrus MJ, Earley TJ, and Patapoutian A (2004) Noxious cold ion channel TRPA1 is activated by pungent compounds and bradykinin. *Neuron* **41**:849–857.
- Bautista DM, Jordt SE, Nikai T, Tsuruda PR, Read AJ, Poblete J, Yamoah EN, Basbaum AI, and Julius D (2006) TRPA1 mediates the inflammatory actions of environmental irritants and proalgesic agents. *Cell* **124**:1269–1282.
- Bautista DM, Movahed P, Hinman A, Axelsson HE, Sterner O, Högestätt ED, Julius D, Jordt SE, and Zygmunt PM (2005) Pungent products from garlic activate the sensory ion channel TRPA1. *Proc Natl Acad Sci U S A* **102**:12248–12252.
- Bidaux G, Flourakis M, Thebault S, Zholos A, Beck B, Gkika D, Roudbaraki M, Bonnal JL, Mauroy B, Shuba Y, et al. (2007) Prostate cell differentiation status determines transient receptor potential melastatin member 8 channel subcellular localization and function. *J Clin Invest* **117**:1647–1657.
- Bisogno T, Hanus L, De Petrocellis L, Tchilibon S, Ponde DE, Brandi I, Schiano Moriello A, Davis JB, Mechoulam R, and Di Marzo V (2001) Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. *Br J Pharmacol* **134**:845–852.



- Caterina MJ, Schumacher MA, Tominaga M, Rosen TA, Levine JD, and Julius D (1997) The capsaicin receptor: a heat-activated ion channel in the pain pathway. *Nature* **389**:816–824.
- Chuang HH, Neuhauser WM, and Julius D (2004) The super-cooling agent icilin reveals a mechanism of coincidence detection by a temperature-sensitive TRP channel. *Neuron* **43**:859–869.
- Corey DP, García-Añoveros J, Holt JR, Kwan KY, Lin SY, Vollrath MA, Amalfitano A, Cheung EL, Derfler BH, Duggan A, et al. (2004) TRPA1 is a candidate for the mechanosensitive transduction channel of vertebrate hair cells. *Nature* **432**:723–730.
- Costa B, Giagnoni G, Franke C, Trovato AE, and Colleoni M (2004) Vanilloid TRPV1 receptor mediates the antihyperalgesic effect of the nonpsychoactive cannabinoid, cannabidiol, in a rat model of acute inflammation. *Br J Pharmacol* **143**:247–250.
- Costa B, Trovato AE, Comelli F, Giagnoni G, and Colleoni M (2007) The nonpsychoactive cannabis constituent cannabidiol is an orally effective therapeutic agent in rat chronic inflammatory and neuropathic pain. *Eur J Pharmacol* **556**:75–83.
- De Petrocellis L, Starowicz K, Schiano Moriello A, Vivese M, Orlando P, and Di Marzo V (2007) Regulation of transient receptor potential channels of melastatin type 8 (TRPM8): effect of cAMP, cannabinoid CB1(1) receptors and endovanilloids. *Exp Cell Res* **313**:1911–1920.
- Di Marzo V and De Petrocellis L (2006) Plant, synthetic, and endogenous cannabinoids in medicine. *Annu Rev Med* **57**:553–574.
- Doerner JF, Gisselmann G, Hatt H, and Wetzel CH (2007) Transient receptor potential channel A1 is directly gated by calcium ions. *J Biol Chem* **282**:13180–13189.
- Felder CC, Joyce KE, Briley EM, Glass M, Mackie KP, Fahey KJ, Cullinan GJ, Hunden DC, Johnson DW, Chaney MO, et al. (1998) LY320135, a novel cannabinoid CB1 receptor antagonist, unmasks coupling of the CB1 receptor to stimulation of cAMP accumulation. *J Pharmacol Exp Ther* **284**:291–297.
- Gatley SJ, Lan R, Pyatt B, Gifford AN, Volkow ND, and Makriyannis A (1997) Binding of the non-classical cannabinoid CP 55,940, and the diarylpyrazole AM251 to rodent brain cannabinoid receptors. *Life Sci* **61**:191–197.
- Hinman A, Chuang HH, Bautista DM, and Julius D (2006) TRP channel activation by reversible covalent modification. *Proc Natl Acad Sci U S A* **103**:19564–19568.
- Jordt SE, Bautista DM, Chuang HH, McKemy DD, Zygmunt PM, Högestätt ED, Meng ID, and Julius D (2004) Mustard oils and cannabinoids excite sensory nerve fibres through the TRP channel ANKTM1. *Nature* **427**:260–265.
- Kobayashi K, Fukuoka T, Obata K, Yamanaka H, Dai Y, Tokunaga A, and Noguchi K (2005) Distinct expression of TRPM8, TRPA1, and TRPV1 mRNAs in rat primary afferent neurons with delta/c-fibers and colocalization with trk receptors. *J Comp Neurol* **493**:596–606.
- Kwan KY, Allchorne AJ, Vollrath MA, Christensen AP, Zhang DS, Woolf CJ, and Corey DP (2006) TRPA1 contributes to cold, mechanical, and chemical nociception but is not essential for hair-cell transduction. *Neuron* **50**:277–289.
- Levine JD and Alessandri-Haber N (2007) TRP channels: targets for the relief of pain. *Biochim Biophys Acta* **1772**:989–1003.
- Ligresti A, Schiano Moriello A, Starowicz K, Matias I, Pisanti S, De Petrocellis L, Laezza C, Portella G, Bifulco M, and Di Marzo V (2006) Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma. *J Pharmacol Exp Ther* **318**:1375–1387.
- Macpherson LJ, Dubin AE, Evans MJ, Marr F, Schultz PG, Cravatt BF, and Pataoutian A (2007) Noxious compounds activate TRPA1 ion channels through covalent modification of cysteines. *Nature* **445**:541–545.
- Mahieu F, Owsianik G, Verbert L, Janssens A, De Smedt H, Nilius B, and Voets T (2007) TRPM8-independent menthol-induced Ca<sup>2+</sup> release from endoplasmic reticulum and Golgi. *J Biol Chem* **282**:3325–3336.
- McKemy DD, Neuhauser WM, and Julius D (2002) Identification of a cold receptor reveals a general role for TRP channels in thermosensation. *Nature* **416**:52–58.
- Obata K, Katsura H, Mizushima T, Yamanaka H, Kobayashi K, Dai Y, Fukuoka T, Tokunaga A, Tominaga M, and Noguchi K (2005) TRPA1 induced in sensory neurons contributes to cold hyperalgesia after inflammation and nerve injury. *J Clin Invest* **115**:2393–2401.
- Premkumar LS, Raisinghani M, Pingle SC, Long C, and Pimentel F (2005) Down-regulation of transient receptor potential melastatin 8 by protein kinase C-mediated dephosphorylation. *J Neurosci* **25**:11322–11329.
- Ruparel NB, Patwardhan AM, Akopian AN, and Hargreaves KM (2008) Homologous and heterologous desensitization of capsaicin and mustard oil responses utilize different cellular pathways in nociceptors. *Pain* **135**:271–279.
- Story GM, Peier AM, Reeve AJ, Eid SR, Mosbacher J, Hricik TR, Earley TJ, Hergarden AC, Andersson DA, Hwang SW, et al. (2003) ANKTM1, a TRP-like channel expressed in nociceptive neurons, is activated by cold temperatures. *Cell* **112**:819–829.
- Thebault S, Lemonnier L, Bidaux G, Flourakis M, Bavencoffe A, Gordienko D, Roudbaraki M, Delcourt P, Panchin Y, Shuba Y, et al. (2005) Novel role of cold/menthol-sensitive transient receptor potential melastatin family member 8 (TRPM8) in the activation of store-operated channels in LNCaP human prostate cancer epithelial cells. *J Biol Chem* **280**:39423–39435.
- Thomas BF, Compton DR, and Martin BR (1990) Characterization of the lipophilicity of natural and synthetic analogs of delta 9-tetrahydrocannabinol and its relationship to pharmacological potency. *J Pharmacol Exp Ther* **255**:624–630.
- Tsavalier L, Shapero MH, Morkowski S, and Laus R (2001) Trp-p8, a novel prostate-specific gene, is up-regulated in prostate cancer and other malignancies and shares high homology with transient receptor potential calcium channel proteins. *Cancer Res* **61**:3760–3769.
- Vellani V, Mapplebeck S, Moriondo A, Davis JB, and McNaughton PA (2001) Protein kinase C activation potentiates gating of the vanilloid receptor VR1 by capsaicin, protons, heat and anandamide. *J Physiol* **534**:813–825.
- Vellani V, Zachrisson O, and McNaughton PA (2004) Functional bradykinin B1 receptors are expressed in nociceptive neurons and are upregulated by the neurotrophin GDNF. *J Physiol* **560**:391–401.
- Wilson RK, Kwan TK, Kwan CY, and Sorger GJ (2002) Effects of papaya seed extract and benzyl isothiocyanate on vascular contraction. *Life Sci* **71**:497–507.
- Xing H, Ling J, Chen M, and Gu JG (2006) Chemical and cold sensitivity of two distinct populations of TRPM8-expressing somatosensory neurons. *J Neurophysiol* **95**:1221–1230.
- Xu H, Delling M, Jun JC, and Clapham DE (2006) Oregano, thyme and clove-derived flavors and skin sensitizers activate specific TRP channels. *Nat Neurosci* **9**:628–635.
- Zhang L and Barritt GJ (2004) Evidence that TRPM8 is an androgen-dependent Ca<sup>2+</sup> channel required for the survival of prostate cancer cells. *Cancer Res* **64**:8365–8373.
- Zurborg S, Yurgionas B, Jira JA, Caspani O, and Heppenstall PA (2007) Direct activation of the ion channel TRPA1 by Ca<sup>2+</sup>. *Nat Neurosci* **10**:277–279.
- Zygmunt PM, Andersson DA, and Hogestatt ED (2002) Delta 9-tetrahydrocannabinol and cannabidiol activate capsaicin-sensitive sensory nerves via a CB1 and CB2 cannabinoid receptor-independent mechanism. *J Neurosci* **22**:4720–4727.

**Address correspondence to:** Dr. Vincenzo Di Marzo, Endocannabinoid Research Group, Institute of Biomolecular Chemistry, Consiglio Nazionale delle Ricerche, Via Campi Flegrei 34, Comprensorio Olivetti, 80078, Pozzuoli (NA), Italy. E-mail: vdimarzo@icmib.na.cnr.it